RNS Number:9566N
Protherics PLC
24 July 2003



   Not for release, publication or distribution in or into the United States,
                           Canada, Australia or Japan


            Recommended Offer by WestLB Panmure Limited ("Panmure")

                                  on behalf of

                         Protherics PLC ("Protherics")

      to acquire the whole of the issued and to be issued share capital of

                           Enact Pharma plc ("Enact")


                  Compulsory acquisition of outstanding shares


Protherics announces that it has received valid acceptances for more than
nine-tenths in nominal value of the Enact Shares to which the Offer relates.
Protherics is therefore entitled to use the procedures set out in sections 428
to 430F (inclusive) of the Companies Act 1985 to acquire compulsorily any Enact
Shares for which it has not received valid acceptances of the Offer.

Panmure, on behalf of Protherics, has today posted statutory notices to
non-assenting shareholders pursuant to sections 428-430F (inclusive) of the
Companies Act 1985 to acquire compulsorily all of the outstanding Enact Shares.

The Offer remains open for acceptance until further notice. Enact Shareholders
who have not yet accepted the Offer are urged to complete and return their Form
of Acceptance as soon as possible.

Terms defined in the Offer Document dated 7 May 2003 have the same meaning in
this press release unless the context otherwise requires.

Enquiries:

Protherics PLC
Andrew Heath, Chief Executive                                      020 7246 9950
Barry Riley, Finance Director                                       01928 518000

Panmure
Dominic Morley                                                     020 7020 5117


The Maitland Consultancy
Brian Hudspith                                                     020 7379 5151

Panmure, which is regulated in the United Kingdom by The Financial Services
Authority, is acting exclusively for Protherics in connection with the Offer and
no-one else and will not be responsible to anyone other than Protherics for
providing the protections afforded to customers of Panmure, nor for giving
advice in relation to the Offer.

The Offer is not being made, directly or indirectly, in or into, or by the use
of the mail of or by any means or instrumentality (including, without
limitation, telephonically or electronically) of interstate or foreign commerce
of, or any facility of a national securities exchange of, the United States,
Canada, Australia or Japan. Accordingly, copies of this announcement are not
being, and must not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in or into or from the United States, Canada, Australia or
Japan and persons receiving this announcement (including custodians, nominees
and trustees) must not mail or otherwise forward, distribute or send it in or
into or from the United States, Canada, Australia or Japan. Doing so may render
invalid any purported acceptance of the Offer. The availability of the Offer to
persons who are not resident in the United Kingdom may be affected by the laws
of the relevant jurisdictions. Any persons who are subject to the laws of any
jurisdiction other than the United Kingdom should inform themselves about and
observe any applicable requirements.

Neither the Protherics Convertible Loan Notes nor the NOIT Shares have been, or
will be, registered under the US Securities Act or under the securities laws of
any state of the United States; the relevant clearances have not been, nor will
they be, obtained from the securities commission of any province or territory of
Canada; no prospectus has been lodged with, or registered by, the Australian
Securities and Investments Commission or the Japanese Ministry of Finance; and
neither the Protherics Convertible Loan Notes nor the NOIT Shares have been, or
will be, registered under or offered in compliance with applicable securities
laws of any state, province, territory or jurisdiction of Canada, Australia or
Japan. Accordingly, neither the Protherics Convertible Loan Notes nor the NOIT
Shares may (unless an exemption under relevant securities laws is applicable) be
offered, sold, resold or delivered, directly or indirectly, in or into the
United States, Canada, Australia or Japan or any other jurisdiction if to do so
would constitute a violation of the relevant laws of, or require registration
thereof in, such jurisdiction or to, or for the account or benefit of, any
United States, Canadian, Australian or Japanese person.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
OUPBIGDRDGDGGXS